GR900100077A - 4-υδροξυθειαζολια ως αναστολεις 5-λιποξυγενασης. - Google Patents

4-υδροξυθειαζολια ως αναστολεις 5-λιποξυγενασης.

Info

Publication number
GR900100077A
GR900100077A GR900100077A GR900100077A GR900100077A GR 900100077 A GR900100077 A GR 900100077A GR 900100077 A GR900100077 A GR 900100077A GR 900100077 A GR900100077 A GR 900100077A GR 900100077 A GR900100077 A GR 900100077A
Authority
GR
Greece
Prior art keywords
hydroxythiazoles
lipoxygenase inhibitors
lipoxygenase
alleviating
enzyme
Prior art date
Application number
GR900100077A
Other languages
English (en)
Inventor
W Dee Brooks
H James Holms
A J Francis Kerdesky
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of GR900100077A publication Critical patent/GR900100077A/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/34—Ethylene-urea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ορισμένες 2-, 4-, 5-υποκαταστημένες ενώσεις του θειαζολίου είναι δυναμικοί αναστολείς του ενζύμου 5-λιποξυγενάσης και συνεπώς είναι ωφέλιμες στη θεραπεία ή την ανακούφιση παθογόνων καταστάσεων οι οποίες περιλαμβάνουν μεταβολικά παραπροϊόντα του μεταβολισμού του αραχιδονικού οξέος. ω
GR900100077A 1989-02-08 1990-02-07 4-υδροξυθειαζολια ως αναστολεις 5-λιποξυγενασης. GR900100077A (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30817789A 1989-02-08 1989-02-08

Publications (1)

Publication Number Publication Date
GR900100077A true GR900100077A (el) 1991-06-28

Family

ID=23192878

Family Applications (1)

Application Number Title Priority Date Filing Date
GR900100077A GR900100077A (el) 1989-02-08 1990-02-07 4-υδροξυθειαζολια ως αναστολεις 5-λιποξυγενασης.

Country Status (11)

Country Link
US (1) US5124342A (el)
EP (1) EP0457803A4 (el)
JP (1) JP2877508B2 (el)
KR (1) KR920701166A (el)
AU (1) AU640637B2 (el)
CA (1) CA2046628A1 (el)
GR (1) GR900100077A (el)
IE (1) IE900394L (el)
IL (1) IL93271A (el)
NZ (1) NZ232369A (el)
WO (2) WO1990009381A1 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645867B2 (en) * 1990-11-30 1994-01-27 Teijin Pharma Limited 2-arylthiazole derivative and pharmaceutical composition containing the same
US5264361A (en) * 1991-03-18 1993-11-23 Lonza Ltd. Microbiological process for the production of 6-hydroxypicolinic acid
IT1254199B (it) * 1992-02-06 1995-09-14 Ministero Dell Uni E Della Tiazolilpirroli ad attivita' fungicida
US5270203A (en) * 1992-03-13 1993-12-14 Lonza Ltd. Biologically pure culture of Alcaligenes faecalis DSM 6335
BR9507598A (pt) 1994-05-04 1997-10-07 Bayer Ag Tiocarboxamidas aromáticas substituídas e seu uso como herbicidas
USRE39263E1 (en) * 1994-05-04 2006-09-05 Bayer Aktiengesellschaft Substituted aromatic thiocarboxylic acid amides and their use as herbicides
CA2167384A1 (en) 1994-05-16 1995-11-23 Hideki Ushio Process for producing tetrazole compound and intermediate therefor
WO1996031211A1 (fr) * 1995-04-07 1996-10-10 Teijin Limited Agent protecteur pour organe ou tissu
WO1997012613A1 (en) * 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5811425A (en) * 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6492398B1 (en) 1999-03-04 2002-12-10 Smithkline Beechman Corporation Thiazoloindolinone compounds
US6624171B1 (en) * 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
MXPA05000200A (es) 2002-07-02 2005-06-06 Schering Corp Nuevos antagonistas del receptor neuropeptido y y5.
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR101164258B1 (ko) 2003-12-23 2012-07-11 아스텍스 테라퓨틱스 리미티드 단백질 키나아제 조절제로서의 피라졸 유도체
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
EP1933832A2 (en) 2005-06-23 2008-06-25 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
WO2007009083A2 (en) * 2005-07-12 2007-01-18 Acadia Pharmaceuticals Inc. Compounds with activity at retinoic acid receptors
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8158801B2 (en) 2005-09-26 2012-04-17 Life Technologies Corporation Violet laser excitable dyes and their method of use
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
TWI403506B (zh) * 2008-06-16 2013-08-01 Faes Farma Sa 用於治療急性和慢性發炎疾病之５－（４－甲磺醯基－苯基）－噻唑衍生物類
US7781594B2 (en) * 2008-06-16 2010-08-24 Faes Farma, S.A. 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
CA3024556A1 (en) * 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
US11110177B2 (en) 2017-11-10 2021-09-07 The Regents Of The University Of Michigan ASH1L degraders and methods of treatment therewith

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260609A (en) * 1977-06-01 1981-04-07 Merck & Co., Inc. Di- and tri- substituted thiazoles
EP0097323A2 (en) * 1982-06-22 1984-01-04 Schering Corporation 2-(4-Pyridyl)-thiazole derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649146A (en) * 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
US4935424A (en) * 1988-05-27 1990-06-19 Warner-Lambert Company 4 or 5-(substituted piperazinylalkyl)-2-aminothiazoles as antipsychotic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260609A (en) * 1977-06-01 1981-04-07 Merck & Co., Inc. Di- and tri- substituted thiazoles
EP0097323A2 (en) * 1982-06-22 1984-01-04 Schering Corporation 2-(4-Pyridyl)-thiazole derivatives

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 108, no. 15, 11th April 1988, page 740, abstract no. 131646m, Columbus, Ohio, US; A.O. GUKASYAN et al.: "(Trihalomethyl)carbinols. I. Synthesis and structure of 2,5-disubstituted thiazolin-4-ones", & ARM. KHIM. ZH. 1986, 39(11), 685-8 *
CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 25, no. 12, December 1977, pages 3270-3276, Tokyo, JP; T. MATSUDA et al.: "Studies on azole compounds. IV. Reaction of 2,5-diarylthiazole 3-oxides with acetic anhydride. Isolation of the intermediates, 4,5-diacetoxy-2,5-diaryl-4,5-dihydrothiazoles" *
CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 30, no. 6, June 1982, pages 1974-1979, Tokyo, JP; M.M. YOUSIF et al.: "Studies on tertiary amine oxides. LXXIV. Reactions of aromatic N-oxides with 2-phenyl-2-thiazolin-4-one in the presence of acetic anhydride" *
CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 33, no. 8, August 1985, pages 3479-3483, Tokyo, JP; T. OKAWARA et al.: "A facile preparation of 4-thiazolone derivatives from thioamides and various haloacyl halides in a biphase system" *
CLAIMS SEARCHED: ALL *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 23, no. 1, January 1980, pages 65-70, American Chemical Society, Washington, DC, US; J.J. BALDWIN et al.: "Heterocyclic analogues of the antihypertensive beta-adrenergic blocking agent (S)-2-[3-(tert-butylamino)-2-hydroxypropoxyÜ-3-cyanopyridine" *
JOURNAL OF ORGANIC CHEMISTRY, vol. 50, no. 10, October 1985, pages 1666-1676, American Chemical Society, Washington, DC, US; K.T. POTTS et al.: "Annulation of the quinazoline ring utilizing mesoionic ring systems" *
JUSTUS LIEBIGS ANNALEN DER CHEMIE, 1978, pages 473-511, Weinheim, DE; G. SATZINGER: "Heterocyclen durch Reaktion von Mercapto- und Hydroxycarbons{ureestern mit aktivierten Nitrilen" *
SYNTHESIS, no. 4, 1976, pages 261-262, Georg Thieme Verlag, Stuttgart, DE; M. FERREY et al.: "A new synthesis of 4-hydroxythiazoles" *
TETRAHEDRON, vol. 41, no. 16, 1985, pages 3297-3302, Pergamon Press Ltd, Oxford, GB; M. BAUDY-FLOC'H et al.: "Etude de la reactivité d'ylures de sulfonium et de pyridinium stabilisés par un groupement cyanoformyle" *

Also Published As

Publication number Publication date
JPH04503212A (ja) 1992-06-11
WO1990009801A1 (en) 1990-09-07
IL93271A (en) 1994-11-11
JP2877508B2 (ja) 1999-03-31
KR920701166A (ko) 1992-08-11
IL93271A0 (en) 1990-11-29
CA2046628A1 (en) 1990-08-09
WO1990009381A1 (en) 1990-08-23
EP0457803A1 (en) 1991-11-27
AU640637B2 (en) 1993-09-02
NZ232369A (en) 1992-01-29
AU5181590A (en) 1990-09-26
US5124342A (en) 1992-06-23
IE900394L (en) 1990-08-08
EP0457803A4 (en) 1991-12-04

Similar Documents

Publication Publication Date Title
GR900100077A (el) 4-υδροξυθειαζολια ως αναστολεις 5-λιποξυγενασης.
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
IT1235693B (it) Transistore ad effetto di campo superficiale con regione di source e/o di drain scavate per dispositivi ulsi.
FI893433A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
IT1131191B (it) Procedimento per la lavorazione di fango di depurazione o di materiale similare
NO984508L (no) Tiazolinsyre-derivater
SE8800238L (sv) Flytande enzymkompositioner
DE69132048T2 (de) Verwendung von Steroiden zur Inhibierung von Angiogenesis
GR1000118B (el) Συνθεσις 1,2-διοξετανων & ενδιαμεσαι ουσιαι δι αυτην.
EE200000093A (et) Agrekanaasi ja maatriksmetalloproteinaaside uudsed inhibiitorid artriidi käitlemiseks
IT9083639A0 (it) Durometro e metodo di misura della durezza di materiali metallici
NO853698L (no) I-substituerte tetralinderivater, fremstilling og anvendel se derav.
DK0489877T3 (da) Antiatherosklerotiske og antithrombotiske 2-amino-6-phenyl-4H-pyran-4-oner
ES2083396T3 (es) Acidos fenilalcan(en)oicos.
ATE58900T1 (de) Diaryldiazolylmethane.
DK162439C (da) Imidazol-2-ylthioalkansyrer og derivater deraf, fremgangsmaader til deres fremstilling samt farmaceutiske praeparater indeholdende disse
ITRM920491A1 (it) Immunosaggio di enzima b12 e procedimento di trattamento di campioni per esso.
DE3863517D1 (de) Verwendung von polyaralkylaminen als korrosionsinhibitoren.
DE68911132D1 (de) Hematopoietische kolonien stimulierende faktoren zur verbesserung des lipoprotein/cholesterin-profils.
NO892189D0 (no) Trijodbenzenforbindelser og kontrastmidler for radiografiinneholdende disse.
ITRM910621A1 (it) Procedimento per la fabbricazione di transistori con struttura gate -isolante -semiconduttore.
DE59310127D1 (de) Benzothiazolderivate als Vulkanisationsbeschleuniger, die sich zur Einführung von polaren Substituenten eignen
NO954344D0 (no) Fremgangsmåte for fremstilling av strykejern med såleplate av stål
DK0490634T3 (da) Quinoliniumsaltmellemprodukter
DE59107537D1 (de) Enzymatische De-Acylierung von Acyl-Aminosorbosen und dessen Verwendung bei der Herstellung von 1-Desoxynojirimicin